clinical trial · NCT05351164
Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
University of Michigan·phase2·active not recruiting·n = 4
Lipomatosis, Multiple SymmetricalMetreleptin
brief summary
Participants (homozygous MFN2 \[gene that provides instructions to produce the Mitofusin 2 protein\] R707W) will be treated with Metreleptin, and effects on body composition, metabolic parameters and safety will be assessed over a 6 month intervention period. Additional safety will be assessed for 1 more year (up to 1.5 years total) in which adverse event data will be collected.
started
Aug 1, 2023
primary completion
Apr 8, 2024
completion
Oct 1, 2028
last updated
Jun 12, 2025
detailed description
In 2024, the IRB granted an amendment that allowed for continued data collection, including adverse events, up to 5 years per participant.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol